

Cover Story
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
By Yiqing Wang
In Brief


Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
- How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough - Why both somatic and germline genomic profiling are essential for precision oncology
- Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?
















